- Home
- SOPH vs PBYI Comparison
SOPH vs PBYI Comparison
Compare SOPH & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | PBYI |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 367.7M | 343.9M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | SOPH | PBYI |
|---|---|---|
| Price | $4.89 | $6.93 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 92.4K | ★ 238.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | $23.09 | N/A |
| Revenue Next Year | $19.57 | N/A |
| P/E Ratio | ★ N/A | $11.31 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $2.58 |
| 52 Week High | $5.70 | $7.68 |
Technical Indicators
Market Signals| Indicator | SOPH | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 62.52 |
| Support Level | $4.54 | $6.32 |
| Resistance Level | $5.31 | $7.25 |
| Average True Range (ATR) | 0.30 | 0.25 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 46.88 | 88.79 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.